{
    "clinical_study": {
        "@rank": "109416", 
        "arm_group": [
            {
                "arm_group_label": "Treatment Group A", 
                "arm_group_type": "Active Comparator", 
                "description": "1 dose of denosumab every 4 weeks for 2 doses, followed by 1 dose of pamidronate every 4 weeks for 2 doses."
            }, 
            {
                "arm_group_label": "Treatment Group B", 
                "arm_group_type": "Active Comparator", 
                "description": "1 dose of pamidronate every 4 weeks for 2 doses, followed by 1 dose of denosumab every 4 weeks for 2 doses."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will estimate the total time for the preparation and administration of denosumab\n      and the total time for the preparation and administration of pamidronate."
        }, 
        "brief_title": "Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Solid Tumor", 
            "Metastatic Bone Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Bone Diseases", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of metastatic bone disease secondary to a solid tumor (eg, breast cancer,\n             lung cancer, etc).\n\n          -  An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\n          -  Subject is one of the following:\n\n               -  being considered for pamidronate IV infusions or denosumab SC injections for\n                  treatment of metastatic bone disease (prescribed per Canadian product\n                  monograph); OR\n\n               -  scheduled to receive pamidronate IV infusions or denosumab SC injections for\n                  treatment of metastatic bone disease (prescribed per Canadian product\n                  monograph); OR\n\n               -  currently receiving pamidronate IV infusions or denosumab SC injections for\n                  treatment of metastatic bone disease AND has received no more than 4 prior\n                  administration of either product combined (prescribed per Canadian product\n                  monograph).\n\n          -  Subject has a serum calcium or albumin-adjusted serum calcium \u2265 2.0 mmol/L (8.0\n             mg/dL) and \u2264 2.9 mmol/L (11.5 mg/dL)\n\n        Exclusion Criteria:\n\n          -  Diagnosis with metastatic bone disease secondary to multiple myeloma or prostate\n             cancer.\n\n          -  Severe renal impairment (creatinine clearance < 30 mL/min)\n\n          -  Subject is being considered for ambulatory pamidronate administration using an\n             infuser device (ie, \"baby bottle\").\n\n          -  A known active infection with Hepatitis B virus or Hepatitis C virus.\n\n          -  Subject has known positive results for human immunodeficiency virus (HIV).Subject has\n             a history of other malignancy within the past 5 years, other than:\n\n               -  Malignancy treated with curative intent and with no known active disease present\n                  for \u2265 5 years before enrollment and felt to be at low risk for recurrence by the\n                  treating physician\n\n               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence\n                  of disease\n\n               -  Adequately treated cervical carcinoma in situ without evidence of disease\n\n               -  Adequately treated breast ductal carcinoma in situ without evidence of disease\n\n               -  Prostatic intraepithelial neoplasia without evidence of prostate cancer\n\n               -  Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in\n                  situ.\n\n          -  Subject has a history or current evidence of osteonecrosis/osteomyelitis of the jaw,\n             active dental or jaw condition that requires oral surgery, non-healed dental/oral\n             surgery, or planned invasive dental procedure over the course of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02101164", 
            "org_study_id": "20120127"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Treatment Group A", 
                    "Treatment Group B"
                ], 
                "description": "Treatment Group A - 1-120 mg SC dose every 4 weeks at Day 1 and week 5 Treatment Group B - 1-120 mg SC dose every 4 weeks at Week 9 and Week 13", 
                "intervention_name": "denosumab", 
                "intervention_type": "Biological", 
                "other_name": "XGEVA"
            }, 
            {
                "arm_group_label": [
                    "Treatment Group A", 
                    "Treatment Group B"
                ], 
                "description": "Treatment Group A - 1-90 mg IV dose every 4 weeks at Week 9 and Week 13 Treatment Group B - 1-90 mg IV dose every 4 weeks at Day 1 and Week 5", 
                "intervention_name": "pamidronate", 
                "intervention_type": "Drug", 
                "other_name": "Aredia"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Pamidronate"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 9, 2014", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-Label, Multicentre Trial to Evaluate the Time Associated With the Preparation and Administration of Denosumab and Pamidronate in Subjects With Solid Tumors and Metastatic Bone Disease in Canada", 
        "overall_contact": {
            "last_name": "Amgen Call Center", 
            "phone": "866-572-6436"
        }, 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Total duration (in hours, minutes and seconds) for investigational product preparation and administration", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Total duration (in hours, minutes and seconds) for investigational product preparation and administration", 
                "safety_issue": "No", 
                "time_frame": "Week 5"
            }, 
            {
                "measure": "Total duration (in hours, minutes and seconds) for investigational product preparation and administration", 
                "safety_issue": "No", 
                "time_frame": "Week 9"
            }, 
            {
                "measure": "Total duration (in hours, minutes and seconds) for investigational product preparation and administration", 
                "safety_issue": "No", 
                "time_frame": "Week 13"
            }
        ], 
        "removed_countries": {
            "country": "Canada"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02101164"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}